Evidence map›Paper›PMID 27479049›Full record

ArticleBiomaterials2016

Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer.

Tzu-Yin Lin, Yuanpei Li, Qiangqiang Liu, Jui-Lin Chen, Hongyong Zhang, Diana Lac, Hua Zhang, Katherine W Ferrara, Sebastian Wachsmann-Hogiu, Tianhong Li and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 102 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Nanomedicine in Bladder Cancer Therapy.International journal of molecular sciences · 2024
    Review
  7. Review
  8. Review
  9. Photodynamic Therapy for Bladder Cancers, A Focused ReviewPhotochemistry and photobiology · 2023
    Review
  10. Review
  11. Review
  12. Phototherapy with Cancer-Specific Nanoporphyrin Potentiates Immunotherapy in Bladder Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Subcutaneous Xenograft Models for Studying PDT In Vivo.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Tzu-Yin LinDepartment of Internal Medicine, University of California Davis, Sacramento, CA 95817, USA. Electronic address: tylin@ucdavis.edu.
Yuanpei LiDepartment of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA 95817, USA.
Qiangqiang LiuDepartment of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA 95817, USA.
Jui-Lin ChenDepartment of Biochemical Science and Technology, National Taiwan University, Taipei 403, Taiwan.
Hongyong ZhangDepartment of Internal Medicine, University of California Davis, Sacramento, CA 95817, USA.
Diana LacDepartment of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA 95817, USA.
Hua ZhangDepartment of Biomedical Engineering, University of California Davis, Sacramento, CA 95817, USA.
Katherine W FerraraDepartment of Biomedical Engineering, University of California Davis, Sacramento, CA 95817, USA.
Sebastian Wachsmann-HogiuDepartment of Pathology and Laboratory Medicine and Center for Biophotonics Science and Technology, University of California Davis, Sacramento, CA 95817, USA.
Tianhong LiDepartment of Internal Medicine, University of California Davis, Sacramento, CA 95817, USA; VA Northern California Health Care System, Mather, CA 95655, USA.
Susan AirhartThe Jackson Laboratory, Bar Harbor, ME 04609, USA.
Ralph deVere WhiteDepartment of Urology, University of California Davis, Sacramento, CA 95817, USA.
Kit S LamDepartment of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA 95817, USA.
Chong-Xian PanDepartment of Internal Medicine, University of California Davis, Sacramento, CA 95817, USA; VA Northern California Health Care System, Mather, CA 95655, USA; Department of Urology, University of California Davis, Sacramento, CA 95817, USA. Electronic address: cxpan@ucdavis.edu.
University of California, Davis · USVA Northern California Health Care System · USJackson Laboratory · USNational Taiwan University · TWUniversity of California System · US

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura Marcu · 2002 to 2026
$84.9M
Specific and high-resolution ultrasound cancer imagingR01CA112356 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI FERRARA, KATHERINE W, FOIRET, JOSQUIN · 2005 to 2022
$6.1M
Ultrasound imaging and enhanced therapeutic responseR01CA134659 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI FERRARA, KATHERINE W · 2009 to 2017
$4.4M
Stimuli-responsive crosslinked theranostics against advanced prostate cancerR01CA199668 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LI, YUANPEI · 2015 to 2019
$1.8M
Smart targeting nano-theranostics for image-guided drug delivery to pediatric brain tumorsR01HD086195 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LI, YUANPEI · 2016 to 2020
$1.6M
Development of targeting nanotherapeutics against bladder cancerI01BX001784 · VA · VA NORTHERN CALIFORNIA HEALTH CARE SYS · PI PAN, CHONG-XIAN · 2014 to 2017
–
BLRD VA I01 BX001784NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA112356NCI NIH HHS R01 CA134659NCI NIH HHS R01 CA199668NICHD NIH HHS R01 HD086195
6 · The paper itself

Abstract

The overall prognosis of bladder cancer has not been improved over the last 30 years and therefore, there is a great medical need to develop novel diagnosis and therapy approaches for bladder cancer. We developed a multifunctional nanoporphyrin platform that was coated with a bladder cancer-specific ligand named PLZ4. PLZ4-nanoporphyrin (PNP) integrates photodynamic diagnosis, image-guided photodynamic therapy, photothermal therapy and targeted chemotherapy in a single procedure. PNPs are spherical, relatively small (around 23 nm), and have the ability to preferably emit fluorescence/heat/reactive oxygen species upon illumination with near infrared light. Doxorubicin (DOX) loaded PNPs possess slower drug release and dramatically longer systemic circulation time compared to free DOX. The fluorescence signal of PNPs efficiently and selectively increased in bladder cancer cells but not normal urothelial cells in vitro and in an orthotopic patient derived bladder cancer xenograft (PDX) models, indicating their great potential for photodynamic diagnosis. Photodynamic therapy with PNPs was significantly more potent than 5-aminolevulinic acid, and eliminated orthotopic PDX bladder cancers after intravesical treatment. Image-guided photodynamic and photothermal therapies synergized with targeted chemotherapy of DOX and significantly prolonged overall survival of mice carrying PDXs. In conclusion, this uniquely engineered targeting PNP selectively targeted tumor cells for photodynamic diagnosis, and served as effective triple-modality (photodynamic/photothermal/chemo) therapeutic agents against bladder cancers. This platform can be easily adapted to individualized medicine in a clinical setting and has tremendous potential to improve the management of bladder cancer in the clinic.

Indexed as

AnimalsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorCombined Modality TherapyDoxorubicinHumansMiceMice, Inbred C57BLMicroscopy, FluorescenceMolecular Targeted TherapyNanoparticlesPeptides, CyclicPhotochemotherapyPhotosensitizing AgentsPhototherapyPorphyrinsDoxorubicinPeptides, CyclicPhotosensitizing AgentsPLZ4 peptidePorphyrinsBladder cancerNanotechnologyPhotodynamic therapyPhotothermal therapy

Identifiers

PMID27479049
PMCPMC5412594
OpenAlexW2475727750

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.